| 產(chǎn)品名稱 |
Hs 445 |
| 商品貨號 |
B164683 |
| Organism |
Homo sapiens, human |
| Tissue |
lymph node |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
2 Cells Contain HERPESVIRUS
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Hodgkin's disease; Hodgkin's lymphoma |
| Age |
56 years |
| Gender |
female |
| Ethnicity |
Caucasian |
| Applications |
Hs 445 was derived in 1970 from an intra-abdominal lymph node of a patient with stage 1 Hodgkin's disease. 0.3% to 0.5% of the cells are positive for EBV early antigen and virion antigen by immunofluorescence. |
| Derivation |
Hs 445 was derived in 1970 from an intra-abdominal lymph node of a patient with stage 1 Hodgkin's disease. |
| Clinical Data |
Hs 445 was derived in 1970 from an intra-abdominal lymph node of a patient with stage 1 Hodgkin's disease. female Caucasian 56 years |
| Tumorigenic |
Yes |
| Effects |
Yes, in X-irradiated or anti lymphocyte serum treated nude mice No, in anti thymocyte serum treated Swiss mice |
| Comments |
Hs 445 was derived in 1970 from an intra-abdominal lymph node of a patient with stage 1 Hodgkin's disease. By electron microscopy, herpesvirus-like particles have been seen. 0.3% to 0.5% of the cells are positive for EBV early antigen and virion antigen by immunofluorescence. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Establish new cultures at 4 X 10 exp5 cells/ml and maintain at between 4 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation |
Culture medium, 95%; DMSO, 5% |
| STR Profile |
Amelogenin: X CSF1PO: 11,10.3 D13S317: 11,13 D16S539: 9,11 D5S818: 9,12 D7S820: 9,10 THO1: 6,7 TPOX: 8 vWA: 14,17 |
| Isoenzymes |
ES-D, 1 G6PD, B GLO-I, 1-2 PGM1, 1 |
| Name of Depositor |
RB Owens |
| Deposited As |
Homo sapiens |
| References |
Arnstein P, et al. Propagation of human tumors in antithymocyte serum-treated mice. J. Natl. Cancer Inst. 52: 71-84, 1974. PubMed: 4544026
Ohsugi Y, et al. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X- irradiated nude mice. J. Natl. Cancer Inst. 65: 715-718, 1980. PubMed: 6932523
|
